The results demonstrated that breast cancer patients with high levels of serum exo-AnxA2 (n = 85) had significantly shorter OS (hazard ratio 2.802; 95% CI = 1.030–7.620; log-rank P = 0.0353) than those with low levels of serum exo-AnxA2 (n = 84; Fig. 3b). This evidence concerns the gene ANXA2 and breast carcinoma.